P07.09.B A RANDOMIZED PHASE 2B STUDY OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)

• Published in: Neuro-oncology (Charlottesville, Va.) Vol. 25; no. Supplement_2; pp. ii52 - ii53
• Main Authors: Ahluwalia, M S, Ciesielski, M, Abad, A, Reardon, D, Aiken, R, Barbaro, M, Sinicrope, K, Peereboom, D M, Odia, Y, Brenner, A, Venur, V, Butowski, N, Belal, A, Qiu, J, Ozair, A, Khosla, A A, Schilero, C, Figel, S, Casucci, D, Mechtler, L, Fenstermaker, R
• Format: Journal Article
• Language: English
• Published: 08.09.2023

Abstract BACKGROUND Newly-diagnosed glioblastoma (nGBM) has a dismal prognosis with a median overall survival (OS) of nearly 16 months. nGBM cells have high expression of tumor-associated survivin protein. Survivin, localized to the cell surface through presentation by MHC class I molecules, is reco...